Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1195 EBV Vaccine in Healthy Participants
NCT05831111Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Apr 2023
- Primary completion
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mRNA-1195 in Epstein-Barr virus infection (14 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions, Number of Participants with Unsolicited Adverse Events and 1 more. Started Apr 2023; status: completed.
02
Drugs
mRNA-1195
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT05831111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831111.